Enveric CEO granted 201,124 RSUs in equity award

Enveric Biosciences, Inc. CEO Joseph Edward Tucker received a grant of 201,124 restricted stock units of common stock under the company’s 2020 Long-Term Incentive Plan.

Rhea-AI Filing Summary

Enveric Biosciences, Inc. CEO Joseph Edward Tucker received a grant of 201,124 restricted stock units of common stock under the company’s 2020 Long-Term Incentive Plan. These RSUs have no cash exercise price; one share of common stock will be issued for each vested unit. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, with an additional one‑thirty‑sixth vesting each month thereafter, and any remaining RSUs vesting on the fourth anniversary, subject to continued employment. Following this award, Tucker directly holds 271,479 shares of common stock.

Insights

Equity compensation analyst

CEO receives time-based RSU grant expanding equity stake.

The CEO of Enveric Biosciences, Joseph Edward Tucker, was granted 201,124 restricted stock units with no purchase price, under the 2020 Long-Term Incentive Plan. Each vested RSU converts into one share of common stock, increasing his potential future ownership.

The vesting schedule is long-dated and time-based: 25% vests after one year, then 1/36 monthly, with full vesting by the fourth anniversary, all conditioned on continued employment. This structure is typical for executive retention rather than a market signal.

After this grant, Tucker directly holds 271,479 common shares according to the filing. The transaction involves no open-market buying or selling, so its significance lies mainly in aligning executive incentives with shareholders over the multi‑year vesting period, not in indicating a view on the current share price.

Insider Trade Summary

Grant/Award: 201,124 shares

Grant/Award 1 txn

Insider Tucker Joseph Edward

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	201,124	$0.00	$0.00

Holdings After Transaction: Common Stock — 271,479 shares (Direct)

Footnotes (1)

1. F1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

Key Figures

RSUs granted: 201,124 units Price per RSU: $0.00 per share Post-transaction holdings: 271,479 shares +3 more

6 metrics

RSUs granted 201,124 units Restricted stock units of common stock granted to CEO

Price per RSU $0.00 per share Stated transaction price for RSU award

Post-transaction holdings 271,479 shares CEO direct common stock ownership after grant

Initial vesting portion One-fourth of RSUs Vests on one-year anniversary of grant date

Ongoing vesting rate 1/36 of RSUs monthly Monthly vesting after first anniversary

Final vesting date Fourth anniversary Any remaining RSUs vest on fourth anniversary

Key Terms

restricted stock units, RSUs, 2020 Long-Term Incentive Plan, vesting, +1 more

5 terms

restricted stock units financial

"Represents the restricted stock units (the "RSUs") granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"For each vested restricted stock unit, the reporting person will be entitled"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

2020 Long-Term Incentive Plan financial

"granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended"

vesting financial

"One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued employment financial

"Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company"

Continued employment means that an individual remains in their current job without interruption. For investors, it signals stability and ongoing work that can affect company performance and future prospects. Like a steady heartbeat for a business, sustained employment helps ensure consistent operations and financial health.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enveric Biosciences (ENVB) CEO receive in this Form 4 filing?

The CEO, Joseph Edward Tucker, received a grant of 201,124 restricted stock units of common stock. These units were awarded under Enveric Biosciences’ 2020 Long-Term Incentive Plan as equity compensation, not purchased in the open market for cash.

How do the Enveric Biosciences (ENVB) RSUs granted to the CEO vest?

The RSUs vest over four years. One-fourth vests on the one-year anniversary of the grant date. Then an additional one-thirty-sixth vests each month, with any remaining units vesting on the fourth anniversary, all conditioned on continued employment with Enveric.

Does the Enveric Biosciences (ENVB) CEO have to pay to receive the RSU shares?

No, the RSUs have a stated price of $0.00 per share in the filing. For each unit that vests, the CEO is entitled to receive one share of Enveric Biosciences common stock without an additional exercise payment.

How many Enveric Biosciences (ENVB) shares does the CEO hold after this RSU grant?

After the reported RSU grant, the Form 4 shows CEO Joseph Edward Tucker directly owning 271,479 shares of Enveric Biosciences common stock. This total reflects his position following the equity award transaction disclosed in the filing.

Is the Enveric Biosciences (ENVB) CEO’s RSU grant an open-market stock purchase?

No, the transaction is coded as an award (code A), meaning a grant of restricted stock units. It is compensation under the company’s long-term incentive plan, not an open-market purchase or sale of Enveric Biosciences shares.

What happens if the Enveric Biosciences (ENVB) CEO leaves before RSUs fully vest?

The filing states vesting is conditioned upon continued employment with Enveric Biosciences. If employment ends before full vesting, any unvested restricted stock units generally would not vest, limiting the CEO’s ability to receive the related shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tucker Joseph Edward

(Last) (First) (Middle)

245 FIRST STREET, RIVERVIEW II

18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		201,124(1)	A	$0	271,479	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

	/s/ Joseph Edward Tucker	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)